8-K: Alphatec Holdings Reports Strong Q2 Results, Raises Full-Year Guidance and Appoints New Board Member

Alphatec Holdings announced a 25% increase in total revenue for the second quarter of 2024, driven by a 27% growth in surgical revenue, and raised its full-year revenue and profitability guidance.

Summary

• Alphatec Holdings, Inc. (ATEC) reported its financial results for the quarter ended June 30, 2024, showing a significant increase in revenue.
• Total revenue reached $146 million, a 25% increase compared to the same quarter last year, with surgical revenue growing by 27%.
• The company's GAAP gross margin was 71%, and non-GAAP gross margin was also 71%.
• GAAP operating expenses were $138 million, while non-GAAP operating expenses were $114 million.
• The company reported a GAAP net loss of $41 million but achieved an adjusted EBITDA of $5.6 million, representing a 4% margin.
• ATEC has increased its full-year 2024 revenue guidance to $602 million, a 25% increase year-over-year, including $537 million from surgical revenue and $65 million from EOS revenue.
• The company also raised its non-GAAP adjusted EBITDA guidance to approximately $25.5 million for the full year.
• The company appointed Keith Valentine, a spine industry veteran, to its Board of Directors.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased guidance, and the appointment of an experienced board member. The company's progress towards profitability and technological advancements also contribute to the positive outlook.

Positives

• The company experienced strong revenue growth, with a 25% increase in total revenue and a 27% increase in surgical revenue.
• Gross margins remained strong at 71% for both GAAP and non-GAAP measures.
• The company achieved positive adjusted EBITDA of $5.6 million, indicating progress towards profitability.
• Full-year revenue and adjusted EBITDA guidance were raised, reflecting management's confidence in future performance.
• The appointment of Keith Valentine to the Board of Directors brings significant industry expertise.
• The launch of EOS Insight is expected to enhance the company's technological capabilities.
• The company saw a 20% growth in new surgeon adoption, a key indicator of future growth.
• The company deployed over $50 million of revenue-generating assets to capitalize on growth opportunities.

Negatives

• The company reported a GAAP net loss of $41 million for the quarter.
• GAAP operating expenses were $138 million, which is significantly higher than the adjusted operating expenses of $114 million.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include the uncertainty of success in developing new products, the ability to execute the strategic operating plan, and the acceptance of the company's products by the surgeon community.
• Other risks include obtaining regulatory clearances, favorable third-party reimbursement, and the ability to meet financial obligations.
• The company is also exposed to product liability, litigation, and patent infringement claims.

Future Outlook

The company expects total revenue to grow 25% to $602 million for the full year 2024, with non-GAAP adjusted EBITDA of approximately $25.5 million.

Management Comments

• Pat Miles, Chairman and Chief Executive Officer, stated that ATEC's procedural thesis perpetuated best-in-class top line growth and fueled the accomplishment of several milestones.
• He also noted that the launch of EOS Insight has begun, enabling the translation of EOS images into unparalleled informatics.
• Miles mentioned that surgeon training reached an all-time high and that the company progressed toward self-funded growth, inflecting to profitability.

Industry Context

This announcement reflects a positive trend in the medical device industry, particularly in the spine surgery sector, where innovation and technological advancements are driving growth. The company's focus on integrating AI and automation into its products aligns with the broader industry trend of leveraging technology to improve surgical outcomes and efficiency.

Comparison to Industry Standards

• Alphatec's 25% revenue growth is strong compared to the broader medical device industry, which typically sees single-digit growth rates.
• Companies like Medtronic and Johnson & Johnson, while much larger, often report lower growth percentages in their medical device segments.
• SeaSpine, where Keith Valentine previously served as CEO, has also been a competitor in the spine market, and ATEC's growth suggests it is gaining market share.
• The adjusted EBITDA margin of 4% is a positive sign, but it is still lower than some established medical device companies that have higher profitability margins.
• The launch of EOS Insight is a significant step for ATEC, as it integrates advanced imaging and AI, which is a competitive advantage compared to companies that rely on traditional imaging methods.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are likely to react positively to the strong financial results and increased guidance.
• Employees may be motivated by the company's growth and progress towards profitability.
• Customers (surgeons) will benefit from the company's innovative products and training programs.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower credit risk due to its improved financial performance.

Next Steps

• The company will continue to focus on expanding its U.S. footprint and driving new surgeon adoption.
• ATEC will continue to deploy revenue-generating assets to capitalize on market opportunities.
• The company will present these results via a live webcast on July 31, 2024.

Key Dates

Keywords

spine surgery, medical devices, surgical revenue, financial results, EBITDA, revenue growth, board of directors, EOS Insight, surgeon training, Alphatec Holdings